Plaque Psoriasis

Previous research indicated that the worsening of different inflammatory cutaneous diseases had been associated with exposure to air pollution.

Dr Lebwohl concludes by giving advice to community physicians and dermatologist on what they can do to improve treating patients with plaque psoriasis.

The panel ponders how they will incorporate the discussed new agents into their plaque psoriasis treatment processes.

The panel each list challenges and unmet needs faced when managing the treatment of plaque psoriasis.

A total of 45 studies were selected for the systematic review, with non-White patients being underrepresented across them all.

Dr. Bagel details newer topical therapies such as tapinarof and roflumilast, and speaks to how greater access to these therapies is needed among psoriasis patients.

Drs Bagel and Lebwohl discuss the new biologic agent, bimekuzumab, and the data results from the phase 3 BE READY trial.

Jerry Bagel, MD, MS, provides and overview of the phase 3 POETYK PSO-1 and POETYK PSO-2 trials, while Leon Kircik, MD, reviews the efficacy and safety of each of them.

Key opinion leaders conclude their discussion on plaque psoriasis by commenting on the potential for research into the genetic origin of disease, possible biomarkers, and treatment options with greater efficacy.

A group of specialists discusses unmet needs in psoriatic disease including physician education about biologics and research about treatment options for pediatric patients, patients with malignancies, and patients who are pregnant.

Dr Lebwohl provides insight on a new class of agents, the TYK2 inhibitors.

Drs Kircik and Stein Gold address roflumilast and tapinarof as new topical agents for the management of plaque psoriasis.

Investigators observed that many patients with psoriasis are not actively seeing a primary care physician and would welcome management of their cardiovascular risk factors.

Matthew Brunner, MHS, PA-C, DFAAPA, highlights the most anticipated developments in the field of treating patients with plaque psoriasis.

Stratification of patients for the treatment of plaque psoriasis based on comorbidities and prior biologic experience.

Dr Lebwohl explains the contraindications for IL-23 inhibitors when using them to treat plaque psoriasis.

Dr Kircik discusses the mechanisms of action involving IL-17 inhibitors when using them as a first-line therapy for plaque psoriasis.

A panel of experts builds a lively discussion on the evolving treatment landscape in plaque psoriasis and highlights the emergence of IL-23 inhibitors as a new class of biologic agents.

Thought leaders in the management of plaque psoriasis share personal insights into factors to consider when treating patients with IL-23 inhibitors, including when to switch biologic agents.

Investigators believe drugs like etanercept and ustekinumab could reduce the risk of psoriatic arthritis in patients with moderate-to-severe chronic plaque psoriasis.

Advanced practice providers discuss scenarios in which they would consider switching between therapies when treating patients with plaque psoriasis.

Lakshi Aldredge, MSN, ANP-BC, DCNP, and Matthew Brunner, MHS, PA-C, DFAAPA share their personal experiences with using IL-23 inhibitors in treating patients with plaque psoriasis.

Mark Lebwohl, MD, and Jerry Bagel, MD, MS, review the currently available TNF-α and IL-12/23 inhibitors used to treat plaque psoriasis.

Spearheaded by Dr Bagel, the panel explores the role of phototherapy in the treatment of plaque psoriasis.

Mechanism of action and dosing of IL-23 inhibitors use to treat plaque psoriasis as explained by advanced practice providers.